Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis

Oncogene

Volumn 29, Issue 11, 2010, Pages 1611-1621

  Dennemarker J ^a   Lohmuller T ^a   Mayerle, J ^b   Tacke, M ^a   Lerch, M M ^b   Coussens, L M ^c,d   Peters, C ^a,e   Reinheckel, T ^a,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cathepsin; Mouse model; Protease; Skin cancer

Indexed keywords

CATHEPSIN L; CATHEPSIN V; CYTOKERATIN 14; GUANOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL INFILTRATION; CONTROLLED STUDY; ENDOSOME; ENZYME ACTIVITY; ENZYME DEFICIENCY; EPIDERMIS; GENOTYPE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOCOMPETENT CELL; KERATINOCYTE; LYSOSOME; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CATHEPSIN L; CELLS, CULTURED; DISEASE PROGRESSION; EPITHELIUM; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-14; KERATINOCYTES; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; TIME FACTORS;

HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

EID: 77949656494     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.466     Document Type: Article

References (48)

1. Abboud-Jarrous G, Atzmon R, Peretz T, Palermo C, Gadea BB, Joyce JA, et al. (2008). Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 283: 18167-18176.
2. Arbeit JM, Munger K, Howley PM, Hanahan D. (1994). Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 68: 4358-4368.
3. Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A, et al. (2003). Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 35: 252-257.
4. Bernard D, Mehul B, Thomas-Collignon A, Simonetti L, Remy V, Bernard MA, et al. (2003). Analysis of proteins with caseinolytic activity in a human stratum corneum extract revealed a yet unidentified cysteine protease and identified the so-called 'stratum corneum thiol protease' as cathepsin L2. J Invest Dermatol 120: 592-600.
5. Bethel PA, Gerhardt S, Jones EV, Kenny PW, Karoutchi GI, Morley AD, et al. (2009). Design of selective cathepsin inhibitors. Bioorg Med Chem Lett 19: 4622-4625.
6. Boudreau F, Lussier CR, Mongrain S, Darsigny M, Drouin JL, Doyon G, et al. (2007). Loss of cathepsin L activity promotes claudin-1 overexpression and intestinal neoplasia. FASEB J 21: 3853-3865.
7. Bromme D. (2004). Cathepsin V. In: Barrett AJ, Rawlings ND, Woessner JF (eds). Handbook of Proteolytic Enzymes. Elsevier: London, pp 1107-1110.
8. Chan RJ, Feng GS. (2007). PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109: 862-867.
9. Cheng T, Hitomi K, van Vlijmen-Willems IM, de Jongh GJ, Yamamoto K, Nishi K, et al. (2006). Cystatin M/E is a high affinity inhibitor of cathepsin V and cathepsin L by a reactive site that is distinct from the legumain-binding site. A novel clue for the role of cystatin M/E in epidermal cornification. J Biol Chem 281: 15893-15899.
10. Coussens LM, Hanahan D, Arbeit JM. (1996). Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol 149: 1899-1917.
11. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, et al. (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 1382-1397.
12. Coussens LM, Tinkle CL, Hanahan D, Werb Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490.
13. Coussens LM, Fingleton B, Matrisian LM. (2002). Matrix metallo-proteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
14. Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, et al. (1999). Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. Apmis 107: 120-127.
15. de Visser KE, Korets LV, Coussens LM. (2005). De novo carcinogen-esis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411-423.
16. de Visser KE, Eichten A, Coussens LM. (2006). Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37.
17. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, et al. (2004). Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol 164: 1131-1139.
18. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. (2000). Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 19: 1187-1194.
19. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, et al. (2006). Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20: 543-556.
20. Gondi CS, Lakka SS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, et al. (2004). Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 64: 4069-4077.
21. Goulet B, Sansregret L, Leduy L, Bogyo M, Weber E, Chauhan SS, et al. (2007). Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation. Mol Cancer Res 5: 899-907.
22. Gutierrez-Fernandez A, Fueyo A, Folgueras AR, Garabaya C, Pennington CJ, Pilgrim S, et al. (2008). Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res 68: 2755-2763.
23. Hagemann S, Gunther T, Dennemarker J, Lohmuller T, Bromme D, Schule R, et al. (2004). The human cysteine protease cathepsin V can compensate for murine cathepsin L in mouse epidermis and hair follicles. Eur J Cell Biol 83: 775-780.
24. Haider AS, Peters SB, Kaporis H, Cardinale I, Fei J, Ott J, et al. (2006). Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol 126: 869-881.
25. Jedeszko C, Sloane BF. (2004). Cysteine cathepsins in human cancer. Biol Chem 385: 1017-1027.
26. Kalluri R. (2003). Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3: 422-433.
27. Liotta LA, Kohn EC. (2001). The microenvironment of the tumour-host interface. Nature 411: 375-379.
28. Lopez-Otin C, Matrisian LM. (2007). Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7: 800-808.
29. Martin MD, Matrisian LM. (2007). The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 26: 717-724.
30. Mayerle J, Schnekenburger J, Kruger B, Kellermann J, Ruthenburger M, Weiss FU, et al. (2005). Extracellular cleavage of E-cadherin by leukocyte elastase during acute experimental pancreatitis in rats. Gastroenterology 129: 1251-1267.
31. Mohamed MM, Sloane BF. (2006). Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6: 764-775.
32. Mueller MM, Fusenig NE. (2004). Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4: 839-849.
33. Navab R, Pedraza C, Fallavollita L, Wang N, Chevet E, Auguste P, et al. (2008). Loss of responsiveness to IGF-I in cells with reduced cathepsin L expression levels. Oncogene 27: 4973-4985.
34. Neel BG, Gu H, Pao L. (2003). The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28: 284-293.
35. Nyberg P, Salo T, Kalluri R. (2008). Tumor microenvironment and angiogenesis. Front Biosci 13: 6537-6553.
36. Reinheckel T, Hagemann S, Dollwet-Mack S, Martinez E, Lohmuller T, Zlatkovic G, et al. (2005). The lysosomal cysteine protease cathepsin L regulates keratinocyte proliferation by control of growth factor recycling. J Cell Sci 118: 3387-3395.
37. Roth W, Deussing J, Botchkarev VA, Pauly-Evers M, Saftig P, Hafner A, et al. (2000). Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J 14: 2075-2086.
38. Schneider MR, Werner S, Paus R, Wolf E. (2008). Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol 173: 14-24.
39. Schubbert S, Shannon K, Bollag G. (2007). Hyperactive ras in developmental disorders and cancer. Nat Rev Cancer 7: 295-308.
40. Tobin DJ, Foitzik K, Reinheckel T, Mecklenburg L, Botchkarev VA, Peters C, et al. (2002). The lysosomal protease cathepsin L is an important regulator of keratinocyte and melanocyte differentiation during hair follicle morphogenesis and cycling. Am J Pathol 160: 1807-1821.
41. Tolosa E, Li W, Yasuda Y, Wienhold W, Denzin LK, Lautwein A, et al. (2003). Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest 112: 517-526.
42. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, et al. (2005). Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 11: 206-213.
43. Vasiljeva O, Papazoglou A, Kruger A, Brodoefel H, Korovin M, Deussing J, et al. (2006). Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 66: 5242-5250.
44. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. (2007). Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 13: 387-403.
45. Vasiljeva O, Korovin M, Gajda M, Brodoefel H, Bojic L, Kruger A, et al. (2008). Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 27: 4191-4199.
46. von Zastrow M, Sorkin A. (2007). Signaling on the endocytic pathway. Curr Opin Cell Biol 19: 436-445.
47. Walz M, Kellermann S, Bylaite M, Andree B, Ruther U, Paus R, et al. (2007). Expression of the human cathepsin L inhibitor hurpin in mice: skin alterations and increased carcinogenesis. Exp Dermatol 16: 715-723.
48. Zheng X, Chou PM, Mirkin BL, Rebbaa A. (2004). Senescence-initiated reversal of drug resistance: specific role of cathepsin L. Cancer Res 64: 1773-1780.